New Trial Testing Teplizumab in Younger Children with Recently Diagnosed Type 1 Diabetes

Teplizumab is a monoclonal antibody designed to slow the immune system's attack on insulin-producing beta cells in the pancreas. At type 1 diabetes onset, the body still produces some insulin—a window of opportunity that typically closes over months to years. Teplizumab aims to preserve that remaining insulin production for as long as possible.

In June 2026, the FDA approved teplizumab for children ages 8–17 with stage 3 type 1 diabetes diagnosed within the previous 8 weeks. The approval was based on accelerated review, meaning the FDA allowed market access earlier than usual based on promising early data showing that teplizumab slows the decline of C-peptide, a marker of insulin production.

Accelerated FDA approval comes with a condition: the manufacturer must complete a confirmatory trial to verify that preserving C-peptide levels translates into meaningful clinical benefits for patients. The BETA-PRESERVE trial is that required study.

By confirming whether delayed insulin loss improves quality of life, reduces hypoglycemia, or changes long-term outcomes, this trial will help doctors and families understand whether teplizumab is truly beneficial in everyday practice.

BETA-PRESERVE is recruiting 723 participants ages 1–25 who were diagnosed with type 1 diabetes within the past 8 weeks. This expands the age range beyond the original approval, including younger children ages 1–7 who have not yet been studied in a large trial.

Participants are randomly assigned to receive either teplizumab or placebo and are followed for 52 weeks. The trial will track C-peptide levels, insulin requirements, and other measures to determine whether teplizumab delivers the clinical benefits suggested by earlier studies.

If you are interested in learning more or joining, visit clinicaltrials.gov and search for study NCT07088068.

This trial represents an important next step in type 1 diabetes treatment. Rather than accepting insulin loss as inevitable, researchers are testing whether we can slow it—potentially giving patients more time with residual insulin production and more stable blood sugar management.

If you or your child was recently diagnosed with type 1 diabetes, you may be eligible to participate. Your diabetes care team can discuss whether clinical trial participation is right for your situation. Participation in research helps answer these critical questions for everyone living with type 1 diabetes.

Origin: T1D Pulse (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.